抑制HMGB1表达促进血管瘤内皮细胞凋亡的机制研究

目的:探讨高迁移率族蛋白B1(HMGB1)对血管瘤内皮细胞(HemECs)活力和凋亡的影响及机制。方法:分离培养人HemECs,将设计并合成的HMGB1小干扰RNA(HMGB1-siRNA)转染HemECs。CCK-8法检测各组细胞活力;流式细胞术检测细胞凋亡率及活性氧(ROS)含量;Western blot检测HMGB1、NF-κB p65、p-IκBα、细胞周期蛋白D1(cyclin D1)和survivin的蛋白表达。结果:与空白对照组比较,转染HMGB1-siRNA的HemECs中HMGB1的蛋白表达显著降低(P0.05)。与NC组比较,转染HMGB1-siRNA的HemECs活力显著降低,凋亡率显著升高,ROS含量显著升高,NF-κB p65、p-IκBα、cyclin D1和survivin的蛋白表达均显著降低(P0.05);且与si-HMGB1组比较,HemECs中加入NF-κB信号通路抑制剂PDTC后,细胞活力抑制、凋亡率和ROS诱导及NF-κB p65、p-IκBα、cyclin D1和survivin的蛋白表达下调更明显(P0.05)。结论:抑制HMGB1表达可降低人HemECs活力和诱导凋亡,机制可能是通过提高ROS含量及下调NF-κB信号通路。

Inhibition of HMGB1 expression promotes apoptosis of hemangioma endothelial cells

AIM: To investigate the effect of inhibiting high-mobility group box protein 1 (HMGB1) expression on the viability and apoptosis of hemangioma endothelial cells (HemECs). METHODS: Human HemECs were isolated and cultured, and HMGB1 small interfering RNA (HMGB1-siRNA) was transfected into the cells. The cell viability was detected by CCK-8 assay. The apoptosis and reactive oxygen species (ROS) content were analyzed by flow cytometry. The protein levels of HMGB1, NF-κB p65, p-IκBα, cyclin D1 and survivin were determined by Western blot. RESULTS: The protein expression of HMGB1 in the HemECs transfected with HMGB1-siRNA was significantly lower than that in blank control group (P<0.05). Compared with NC group, the cell viability was decreased significantly in the HemECs transfected with HMGB1-siRNA, the apoptotic rate was significantly increased, the content of ROS increased significantly, and the protein levels of NF-κB p65, p-IκBα, cyclin D1 and survivin were significantly decreased (P<0.05). After exposure to NF-κB signaling pathway inhibitor PDTC, the cell viability was inhibited, the apoptosis was increased, ROS content, and the protein levels of NF-κB p65, p-IκBα, cyclin D1 and survivin were down-regulated significantly, as compared with si-HMGB1 group (P<0.05). CONCLUSION: Inhibition of HMGB1 reduces the viability of HemECs and induces apoptosis by increasing the content of ROS and down-regulating the activity of NF-κB signaling pathway.